Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Feasibility of a Community-Based Multimodal Exercise Programme in Parkinson's Disease

1. června 2026 aktualizováno: Mario González Iglesias, Universidad Rey Juan Carlos

Feasibility and Preliminary Effectiveness of an Individualised Multimodal Group-Based Exercise Programme for People With Parkinson's Disease: A Non-Randomized Feasibility Study

This study aims to evaluate the feasibility and preliminary effectiveness of a multimodal, group-based but individualised therapeutic exercise programme for people with Parkinson's disease delivered within a real-world community-based patient association setting.

The primary objective is to assess the feasibility of implementing the programme, including recruitment, consent, adherence, intervention completion, acceptability, perceived exertion and safety. Secondary objectives are to obtain preliminary comparative information regarding the effects of the intervention on motor and non-motor symptoms, physical fitness, pain-related outcomes and exercise-induced hypoalgesia.

This is a non-randomized sequential feasibility study including an intervention group participating in a 12-week multimodal exercise programme and a matched non-exercise control group maintaining usual activities. Outcomes will be assessed at baseline, post-intervention and 6-month follow-up.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder characterised by motor symptoms such as bradykinesia, rigidity and tremor, as well as non-motor symptoms including pain, fatigue, sleep disturbances, cognitive impairment and psychiatric symptoms. Although pharmacological management is effective for several motor manifestations, many non-motor symptoms respond poorly to dopaminergic therapy, highlighting the need for complementary non-pharmacological interventions.

Exercise therapy has shown beneficial effects on both motor and non-motor symptoms in people with Parkinson's disease. However, it remains necessary to determine whether exercise programmes supported by the scientific literature can be feasibly implemented within real-world community environments frequently attended by patients, such as Parkinson's disease associations. In these settings, exercise interventions are commonly delivered in generic group-based formats despite the substantial heterogeneity in symptom severity, functional capacity and disease progression among participants. Therefore, there is also a need to design exercise programmes that allow individualised adjustment of exercise prescription parameters, including intensity and progression criteria, in order to optimize the potential effects of exercise on Parkinson's disease symptoms while maintaining safety and feasibility in community-based group settings.

The present study aims to evaluate the feasibility of implementing a multimodal, group-based but individualised therapeutic exercise programme within a real-world Parkinson's disease association setting. Feasibility outcomes include consent and recruitment rates, adherence, intervention completion, trial completion, acceptability, perceived exertion, treatment-decision rate and safety. Control group recruitment and assessment completion will be reported descriptively as operational information related to the exploratory comparison group, but they will not determine the primary feasibility assessment of the intervention.

Secondary objectives are to obtain preliminary comparative information regarding the potential effectiveness of the intervention on motor and non-motor symptoms, gait, balance, physical fitness, pain-related outcomes and exercise-induced hypoalgesia.

This study uses a non-randomized sequential feasibility design. Recruitment of the intervention group as a cohort was necessary to implement the group exercise programme under realistic conditions and to evaluate intervention-related feasibility outcomes. To provide preliminary comparative information regarding effectiveness, a matched non-exercise control group was included.

Frequency matching will be used at the group level according to sex, 10-year age categories and Hoehn & Yahr stage categories (1-1.5, 2-2.5 and 3). Individual 1:1 matching will not be required. This approach was selected to reduce baseline imbalance while maintaining the feasibility of recruitment within a real-world community setting.

The sample size was determined according to the primary feasibility objective, specifically the precision of the estimated adherence rate. Assuming an expected adherence rate of approximately 80%, 28 participants would provide an estimation precision of approximately ±15% with a 95% confidence interval. Considering potential attrition, the intervention group sample size was increased to 32 participants. A matched non-exercise control group of 32 participants will also be recruited, resulting in a total target sample size of 64 participants.

Participants with Hoehn & Yahr stages 1-3 will be recruited from Asociación Parkinson Madrid and other Parkinson's disease associations in the Madrid region.

The intervention group will participate in a 12-week multimodal exercise programme consisting of two weekly supervised face-to-face sessions and one weekly home-based session. The programme includes strength training, cardiovascular/balance exercise and cognitive-motor exercises. Exercise prescription and progression were individualised according to participant tolerance, functional capacity, motor performance, and safety considerations.

Training intensity was monitored and adjusted using 10-repetition maximum principles, repetitions in reserve (RIR), and perceived exertion scales including OMNI-RES and Borg ratings. Exercise prescription and progression were individualised according to participant tolerance, functional capacity, motor performance, and safety considerations. All supervised sessions were delivered by physiotherapists experienced in neurological rehabilitation and exercise prescription for Parkinson's disease.

Outcomes will be assessed at baseline, post-intervention and 6-month follow-up.

Feasibility outcomes will be analysed descriptively using frequencies, percentages, means and confidence intervals where appropriate. Secondary clinical outcomes measured at baseline, post-intervention and 6-month follow-up will be analysed using linear mixed-effects models including group, time and group-by-time interaction effects. Estimated between-group differences, 95% confidence intervals and effect sizes will be reported. Given the feasibility nature of the study and the non-randomized sequential design, efficacy analyses will be interpreted as exploratory and hypothesis-generating rather than confirmatory.

Typ studie

Intervenční

Zápis (Odhadovaný)

64

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Mario González Iglesias, MSc PhD Student, Physiotherapy
  • Telefonní číslo: +34 622113365
  • E-mail: mario.gonzalez@urjc.es

Studijní záloha kontaktů

  • Jméno: Yeray González Zamorano, PhD, Physiotherapy
  • Telefonní číslo: +34 689105357
  • E-mail: yeray.gonzalez@urjc.es

Studijní místa

  • Španělsko
    • Madrid
      • Alcorcón, Madrid, Španělsko, 28922
        • Nábor
        • Universidad Rey Juan Carlos

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Eligibility Criteria The eligibility criteria will be identical for both the experimental and control groups. However, this study will employ a sequential recruitment design. Participants for the control group will be recruited following the experimental group and will be matched (1:1 ratio) based on sex, age (± 5 years), and disease severity according to the Hoehn & Yahr (H&Y) scale.

Inclusion Criteria:

  • Subjects diagnosed with Idiopathic Parkinson's Disease according to the UK Parkinson's Disease Society Brain Bank Diagnostic Criteria.
  • Subjects staged between 1 and 3 on the Hoehn & Yahr Scale. For matching purposes, stage 1 includes stage 1.5, and stage 2 includes stage 2.5.

Exclusion Criteria:

  • Subjects diagnosed with a neurological disease other than PD.
  • Those diagnosed with a cardiovascular, respiratory, or metabolic disease or other conditions that represent a contraindication to physical exercise.
  • Those who have suffered an exacerbation or hospitalization in the last three months prior to starting the assessment protocol or during the therapeutic intervention process.
  • Those who have received a course of steroids, intravenously or orally, six months prior to the start of the study or during the therapeutic intervention process.
  • Those with cognitive impairment (defined as a score < 21 on the Montreal Cognitive Assessment, MoCA) or language impairments that prevent adequate communication, comprehension, or following of exercise instructions.
  • Participation in a structured, individualized strength and/or aerobic exercise program within the three months prior to enrollment.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Žádný zásah: Control Group
Participants from the control group will be asked to keep their usual treatment for the duration of the study.
Experimentální: Exercise group
Two weekly in-person sessions of multimodal exercise that involve strength training, aerobic interval training / balance and coordination training and a cognitive-motor exercise, each session lasting 55-60 minutes. Additionally, one weekly home session lasting 25-30 minutes that include strength and aerobic training.
Jiný: Exercise Group

In-person session structure: 1) Warm-up for 4 minutes; 2) 4 strength exercises for upper limps, trunk and lower limbs with free weights and elastic bands (3 sets per exercise); 3) Moderate to vigorous aerobic interval training / balance and coordination training (4 stations for 40 seconds, 2 sets); 4) Cognitive-motor exercise for 10 minutes; 5) Stretching and cool-down for 3 minutes.

Home session structure: 1) Warm-up for 4 minutes; 2) 3 strength exercises for upper limbs, trunk and lower limbs (3 sets per exercise); 3) Moderate to vigorous aerobic interval training (4 stations for 40 seconds, 2 sets); 4) Stretching and cool-down for 3 minutes

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Consent rate
Časové okno: Baseline
It will be asessed as the proportion of individuals who provided informed consent relative to the number of individuals invited to participate
Baseline
Recruitment rate
Časové okno: Baseline
It will be evaluated as the proportion of enrolled participants relative to the number of eligible participants screened
Baseline
Adherence rate
Časové okno: Post-intervention (At 12 weeks from the start of the programme)
Adherence rate will be assessed as the proportion of completed sessions relative to the scheduled sessions
Post-intervention (At 12 weeks from the start of the programme)
Intervention completion rate
Časové okno: Post-intervention (At 12 weeks from the start of the programme)
It will be evaluated as the proportion of participants who completed at least 80% of sessions.
Post-intervention (At 12 weeks from the start of the programme)
Trial completion rate
Časové okno: At 39 weeks from the start of the programme
It will be assessed as the proportion of participants who completed all assessments
At 39 weeks from the start of the programme
Proportion of adverse events
Časové okno: Post-intervention (At 12 weeks from the start of the programme)
Safety will be reported as the proportion of adverse events, defined as the proportion of participants who experienced adverse events (e.g., falls, pain, fatigue)
Post-intervention (At 12 weeks from the start of the programme)
Treatment-decision rate
Časové okno: Post-intervention (At 12 weeks from the start of the programme)
Defined as the proportion of exercises that required modification due to fall-risk considerations
Post-intervention (At 12 weeks from the start of the programme)
Change in Theoretical Framework Acceptability Questionnaire
Časové okno: At 12 weeks from Baseline
It is a questionnaire specifically desgined to assess acceptability of healthcare interventions. It consists of 7 domains: 1) Affective attitude, 2) Burden, 3) Ethicality, 4)Perceived efectiveness, 5) Intervention coherence, 6) Self efficacy, 7) Opportinity costs 8) General acceptability.
At 12 weeks from Baseline
Client Satisfaction Questionnaire (CSQ-8)
Časové okno: Post-intervention (12 weeks from baseline)
It contains 8 dimensions measuring satisfaction with the care and treatment received. The total score is 32 points, with higher scores indicating greater satisfaction. Dimensions related to satisfaction with the training modality and tool used (entertainment, ease of use, accessibility, among others), the professional who applies it (clear explanation, availability, ability to adapt, among others) or recommendation to other patients will be evaluated.
Post-intervention (12 weeks from baseline)
Average Rating of Perceived Exertion (RPE) during Resistance Training
Časové okno: Through study completion (average across 12 weeks)
The average perceived effort reported by the participants across all strength training sessions over the 12-week intervention. This will be assessed using the OMNI-Resistance Exercise Scale (OMNI-RES), which ranges from 0 ("extremely easy") to 10 ("extremely hard"). Higher scores indicate a greater perception of effort during the execution of strength exercises
Through study completion (average across 12 weeks)
Average Rating of Perceived Exertion (RPE) during Cardiorespiratory Exercise
Časové okno: Through study completion (average across 12 weeks)
The average intensity of effort perceived by the participants during all cardiorespiratory training sessions. This will be measured using the Borg Rating of Perceived Exertion (RPE) 6-20 Scale. The scale ranges from 6 (no exertion at all) to 20 (maximal exertion). This metric reflects the global subjective strain experienced during aerobic activities throughout the 12-week program.
Through study completion (average across 12 weeks)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Unified Parkinson Disease Rating Scale Part 3 (UPDRS-3)
Časové okno: At 12 weeks from Baseline
This scale evaluates the severity of those motor symptoms linked to the disease such as tremor, rigidity, bradikinesia, postural instability and gait distubances. It consists of 18 items that are scored from 0 (no disturbance) to 4 (maximum disturbance)
At 12 weeks from Baseline
Change in Unified Parkinson Disease Rating Scale Part 3 (UPDRS-3)
Časové okno: At 39 weeks from Baseline
This scale evaluates the severity of those motor symptoms linked to the disease such as tremor, rigidity, bradikinesia, postural instability and gait distubances. It consists of 18 items that are scored from 0 (no disturbance) to 4 (maximum disturbance)
At 39 weeks from Baseline
Change in Balance Berg Scale
Časové okno: At 12 weeks from Baseline
This scale measures static and dynamic balance through 14 tasks. Each task is scored from 0 (worst score) to 4 (best score)
At 12 weeks from Baseline
Change in Balance Berg Scale
Časové okno: At 39 weeks from Baseline
This scale measures static and dynamic balance through 14 tasks. Each task is scored from 0 (worst score) to 4 (best score)
At 39 weeks from Baseline
Change in Non-Motor Symptoms Scale (NMSS)
Časové okno: At a 12 weeks from Baseline
It is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions: 1) Cardiovascular, 2) Sleep/fatigue, 3) Mood/apathy, 4) Perceptual problems/hallucinations, 5) Attention/memory, 6) Gastrointestinal tract, 7) Urinary, 8) Sexual function and 9) Miscellaneous.
At a 12 weeks from Baseline
Change in Non-Motor Symptoms Scale (NMSS)
Časové okno: At a 39 weeks from Baseline
It is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions: 1) Cardiovascular, 2) Sleep/fatigue, 3) Mood/apathy, 4) Perceptual problems/hallucinations, 5) Attention/memory, 6) Gastrointestinal tract, 7) Urinary, 8) Sexual function and 9) Miscellaneous.
At a 39 weeks from Baseline
Change in 10 Repetition Maximum (10-RM)
Časové okno: At 12 weeks from Baseline
The 10-RM is the maximum amount of weight a person can lift exactly 10 times with correct technique, without being able to perform an eleventh repetition. 10-RM for military press with dumbbells, lunges with dumbbells, deadlift with barbell and row with barbell will be assessed.
At 12 weeks from Baseline
Change in Isometric Handgrip Strength
Časové okno: At 12 weeks from Baseline
A dynamometer is used to measure the maximum handgrip strength with both hands for three times. The mean is obtained after the three attempts.
At 12 weeks from Baseline
Change in Isometric Handgrip Strength
Časové okno: At 39 weeks from Baseline
A dynamometer is used to measure the maximum handgrip strength with both hands for three times. The mean is obtained after the three attempts.
At 39 weeks from Baseline
Change in Dynamic Fatigability
Časové okno: At 12 weeks from Baseline
A dynamometer is employed and the subject is asked to perform 15 consecutive maximum handgrip contractions.
At 12 weeks from Baseline
Change in Dynamic Fatigability
Časové okno: At 39 weeks from Baseline
A dynamometer is employed and the subject is asked to perform 15 consecutive maximum handgrip contractions.
At 39 weeks from Baseline
Change in Five Times Sit to Stand Test
Časové okno: At 12 weeks from Baseline
This test measures lower limbs power. The subject is asked to stand up and sit down on a chair as quicky as possible for five times while the therapist measures the time. Two attempts are performed to calculate the mean.
At 12 weeks from Baseline
Change in Five Times Sit to Stand Test
Časové okno: At 39 weeks from Baseline
This test measures lower limbs power. The subject is asked to stand up and sit down on a chair as quicky as possible for five times while the therapist measures the time. Two attempts are performed to calculate the mean.
At 39 weeks from Baseline
Change in 6 Minute Walk Test
Časové okno: At 12 weeks from Baseline
This test assesses the distance a person is capable to walk as fast as possible for 6 minutes.
At 12 weeks from Baseline
Change in 6 Minute Walk Test
Časové okno: At 39 weeks from Baseline
This test assesses the distance a person is capable to walk as fast as possible for 6 minutes on a 15 metres long corridor.
At 39 weeks from Baseline
Change in Functional Movement Screen
Časové okno: At 12 weeks from Baseline
This scale consists of seven motor tasks that measure the quality of movement in different body segments. Each task is scored from (worst score) 0 to 3 (best score).
At 12 weeks from Baseline
Change in King´s Parkinson´s Disease Pain Scale score
Časové okno: At 12 weeks from Baseline

Parkinson´s Disease specific scale that evaluates the localization, frequency, and intensity of pain. It has 14 items distributed in 7 domains: 1. Musculoskeletal Pain; 2. Chronic Pain; 3. Fluctuation-related Pain; 4. Nocturnal Pain; 5.

Oro-facial Pain; 6. Discoloration, Oedema/Swelling Pain; 7. Radicular Pain. Each item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 to 12, the sum of which gives the total score with a theoretical range from 0 to 168, with higher scores indicating more severity and frequency of pain.
At 12 weeks from Baseline
Change in King´s Parkinson´s Disease Pain Scale score
Časové okno: At 39 weeks from Baseline

Parkinson´s Disease specific scale that evaluates the localization, frequency, and intensity of pain. It has 14 items distributed in 7 domains: 1. Musculoskeletal Pain; 2. Chronic Pain; 3. Fluctuation-related Pain; 4. Nocturnal Pain; 5.

Oro-facial Pain; 6. Discoloration, Oedema/Swelling Pain; 7. Radicular Pain. Each item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 to 12, the sum of which gives the total score with a theoretical range from 0 to 168, with higher scores indicating more severity and frequency of pain.
At 39 weeks from Baseline
Change in Brief Pain Inventory
Časové okno: At 12 weeks from Baseline
It assess the severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours.
At 12 weeks from Baseline
Change in Brief Pain Inventory
Časové okno: At 39 weeks from Baseline
It assess the severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours.
At 39 weeks from Baseline
Change in Pressure Pain Threshold
Časové okno: At 12 weeks from Baseline
Two Pain Pressure Thresholds will be measured by a handheld algometer, one over the most painful area (peripheric hyperalgesia) and the other one over the middle of the distal phalanx of the thumb (central hyperalgesia). The Pain Pressure Threshold will be applied with the algometer perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain. 3 measures with 30-seconds rest between them will be performed, taking the average as Pain Pressure Threshold.
At 12 weeks from Baseline
Change in Pressure Pain Threshold
Časové okno: At 39 weeks from Baseline
Two Pain Pressure Thresholds will be measured by a handheld algometer, one over the most painful area (peripheric hyperalgesia) and the other one over the middle of the distal phalanx of the thumb (central hyperalgesia). The Pain Pressure Threshold will be applied with the algometer perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain. 3 measures with 30-seconds rest between them will be performed, taking the average as Pain Pressure Threshold.
At 39 weeks from Baseline
Change in Conditioned Pain Modulation
Časové okno: At 12 weeks from Baseline
Assesses the descending pain modulatory system. The Pain Pressure Threshold will be assessed in the middle of the distal phalanx of the thumb with a handheld algometer, corresponding to the first test stimulus. Afterward, the patient will immerse the contrary hand up to the wrist into stirred ice-cold water (0-4º) maintaining it for 3 minutes corresponding to the conditioning stimulus. If the pain is unbearable before the 3 minutes, the patient will be able to remove his/her hand. Immediately after removing the hand, a second Pain Pressure Threshold measure will be performed in the same place as the first one, corresponding to the second test stimulus.
At 12 weeks from Baseline
Change in Conditioned Pain Modulation
Časové okno: At 39 weeks from Baseline
Assesses the descending pain modulatory system. The Pain Pressure Threshold will be assessed in the middle of the distal phalanx of the thumb with a handheld algometer, corresponding to the first test stimulus. Afterward, the patient will immerse the contrary hand up to the wrist into stirred ice-cold water (0-4º) maintaining it for 3 minutes corresponding to the conditioning stimulus. If the pain is unbearable before the 3 minutes, the patient will be able to remove his/her hand. Immediately after removing the hand, a second Pain Pressure Threshold measure will be performed in the same place as the first one, corresponding to the second test stimulus.
At 39 weeks from Baseline
Change in Exercise-Induced Hypoalgesia
Časové okno: At 12 weeks from Baseline
Exercise-Induced Hypoalgesia is a phenomenom in which pain sensitivity is reduced after a single bout of exercise. Pain sensitivity will be assessed before and immediately after the 6 minute walk test. Pain sensitivity will be measured with a handheld algometer on the dominant quadriceps and on the non-dominant trapezius for two times. The algometer will be placed perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain.
At 12 weeks from Baseline
Change in Exercise-Induced Hypoalgesia
Časové okno: At 39 weeks from Baseline
Exercise-Induced Hypoalgesia is a phenomenom in which pain sensitivity is reduced after a single bout of exercise. Pain sensitivity will be assessed before and immediately after the 6 minute walk test. Pain sensitivity will be measured with a handheld algometer on the dominant quadriceps and on the non-dominant trapezius for two times. The algometer will be placed perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain.
At 39 weeks from Baseline
Change in Tampa Scale of Kinesiophobia
Časové okno: At 12 weeks from Baseline
Measures fear of movement-related pain. Its scores range from 11-44 points with higher scores indicating greater fear of pain, movement, and injury
At 12 weeks from Baseline
Change in Tampa Scale of Kinesiophobia
Časové okno: At 39 weeks from Baseline
Measures fear of movement-related pain. Its scores range from 11-44 points with higher scores indicating greater fear of pain, movement, and injury
At 39 weeks from Baseline
Pain Catastrophizing Scale
Časové okno: At 12 weeks from Baseline
Measures catastrophizing thinking. Its total score range from 0-52, along with three subscale scores assessing rumination, magnification and helplessness, with higher scores indicating higher level of catastrophizing.
At 12 weeks from Baseline
Pain Catastrophizing Scale
Časové okno: At 39 weeks from Baseline
Measures catastrophizing thinking. Its total score range from 0-52, along with three subscale scores assessing rumination, magnification and helplessness, with higher scores indicating higher level of catastrophizing.
At 39 weeks from Baseline
Change In Fatigue Severity Scale
Časové okno: At 12 weeks from Baseline
It is a validated 9-item scale for PD that measures the long-term functional impact of fatigue. Each item is scored from 1 (Disagree) to 7 (Agree).
At 12 weeks from Baseline
Change In Fatigue Severity Scale
Časové okno: At 39 weeks from Baseline
It is a validated 9-item scale for PD that measures the long-term functional impact of fatigue. Each item is scored from 1 (Disagree) to 7 (Agree).
At 39 weeks from Baseline
Change in Parkinson's Disease Sleep Scale 2 (PDSS-2)
Časové okno: At 12 weeks from Baseline
This scale contains 15 items that measures the level of sleep disruption. The questionnaire asks about the frequency of the sleep disturbances from "never" to "very often".
At 12 weeks from Baseline
Change in Parkinson's Disease Sleep Scale 2 (PDSS-2)
Časové okno: At 39 weeks from Baseline
This scale contains 15 items that measures the level of sleep disruption. The questionnaire asks about the frequency of the sleep disturbances from "never" to "very often".
At 39 weeks from Baseline
Change in State-Trait Anxiety Inventory
Časové okno: At 12 weeks from Baseline
Measures anxious states and anxious traits. It has 20 items for assessing trait anxiety and 20 for state anxiety. All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.
At 12 weeks from Baseline
Change in State-Trait Anxiety Inventory
Časové okno: At 39 weeks from Baseline
Measures anxious states and anxious traits. It has 20 items for assessing trait anxiety and 20 for state anxiety. All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.
At 39 weeks from Baseline
Change in Beck Depression Inventory
Časové okno: At 12 weeks from Baseline
Measures depressive symptoms. Scores range from 0 to 63 leading to 6 groups: 0-10, normal; 11-16, mild mood disturbance; 17-20, borderline clinical depression; 21-30, moderate depression; 31-40, severe depression; and over 40, extreme depression.
At 12 weeks from Baseline
Change in Beck Depression Inventory
Časové okno: At 39 weeks from Baseline
Measures depressive symptoms. Scores range from 0 to 63 leading to 6 groups: 0-10, normal; 11-16, mild mood disturbance; 17-20, borderline clinical depression; 21-30, moderate depression; 31-40, severe depression; and over 40, extreme depression.
At 39 weeks from Baseline
Change in Global Physical Activity Questionnaire (GPAQ)
Časové okno: At 12 weeks from Baseline
It is a questionnaire that consists of 15 questions about physical activity at work, during commutes and in leisure time, and an additional question about sedentary behaviour during a typical week. This questionnaire provides a numerical result in METs, such that the more active the person is, the more METs the instrument reflects.
At 12 weeks from Baseline
Change in Global Physical Activity Questionnaire (GPAQ)
Časové okno: At 39 weeks from Baseline
It is a questionnaire that consists of 15 questions about physical activity at work, during commutes and in leisure time, and an additional question about sedentary behaviour during a typical week. This questionnaire provides a numerical result in METs, such that the more active the person is, the more METs the instrument reflects.
At 39 weeks from Baseline

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Universidad Rey Juan Carlos

Spolupracovníci

Asociación Parkinson Madrid

Vyšetřovatelé

  • Vrchní vyšetřovatel: Mario González Iglesias, Physiotherapy, Universidad Rey Juan Carlos

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

8. září 2025

Primární dokončení (Odhadovaný)

1. června 2026

Dokončení studie (Odhadovaný)

1. září 2027

Termíny zápisu do studia

První předloženo

25. května 2026

První předloženo, které splnilo kritéria kontroly kvality

25. května 2026

První zveřejněno (Aktuální)

1. června 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

3. června 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

1. června 2026

Naposledy ověřeno

1. června 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 090420253882025

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Individual anonymized participant data will be available to other researchers under request.

Časový rámec sdílení IPD

Six months at the end of the study.

Kritéria přístupu pro sdílení IPD

Individual anonymized participant data will be available to other researchers under request.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA
  • ICF

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na PARKINSONOVA NEMOC (porucha)

Klinické studie na Exercise Group

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Turkmenistan

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit